Status message

Active context: kki_bg_colors_yellow

A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible Dose, Parallel-Group Study To Evaluate The Efficacy And Safety Of Lurasidone In Children And Adolescent Subjects With Bipolar I Depression

Principal Investigator:

To evaluate the efficacy of lurasidone (20 - 80 mg/day flexibly dosed) compared with placebo in children and adolescent subjects with bipolar I disorder, most recent episode depressed, with or without rapid cycling disease course, and without psychotic features (diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. [DSM-V] criteria) as measured by the change from Baseline in the Children's Depression Rating Scale, Revised (CDRS-R) total score.

Kennedy Krieger Institute Announces Retirement of President and CEO

Dr. Gary W. GoldsteinThe Institute’s board of directors is conducting a national search and is expected to name a new CEO in the coming months.
Learn more.


Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.